Identification of a new class of HBV capsid assembly modulator.
Kuduk, S.D., Stoops, B., Alexander, R., Lam, A.M., Espiritu, C., Vogel, R., Lau, V., Klumpp, K., Flores, O.A., Hartman, G.D.(2021) Bioorg Med Chem Lett 39: 127848-127848
- PubMed: 33610748
- DOI: https://doi.org/10.1016/j.bmcl.2021.127848
- Primary Citation of Related Structures:
7K5M - PubMed Abstract:
The HBV core protein is a druggable target of interest due to the multiple essential functions in the HBV life cycle to enable chronic HBV infection. The core protein oligomerizes to form the viral capsid, and modulation of the HBV capsid assembly has shown efficacy in clinical trials. Herein is described the identification and hit to lead SAR of a novel series of pyrazolo piperidine HBV capsid assembly modulators.
Organizational Affiliation:
Novira Therapeutics, a Janssen Pharmaceuticals Company, 1400 McKean Road, Spring House, PA 19477, United States. Electronic address: skuduk@its.jnj.com.